Healing of grade-II and III oesophagitis through motility stimulation with cisapride.
The clinical relevance of cispride's stimulating effects on lower oesophageal motility was studied in 19 patients with documented (endoscopy, biopsy) grade II or III oesophagitis. Patients were treated for 8 or 16 weeks (depending essentially on whether the result was cure or failure) with 10 mg of cisapride four times a day (n = 11) or placebo (n = 8). Cisapride was superior to placebo with regard to mucosal healing (p less than 0.001) and symptomatic improvement (p less than 0.05): at the end of treatment, healing (grade 0) was observed in 8 cisapride patients, against 1 placebo patient, and reflux symptoms had disappeared in 7 and 1 patients, respectively. In conclusion, cisapride was of significant benefit to oesophagitis patients and was well tolerated.
Lepoutre
L
L
Gastroenterological Unit of O.L.V. Hospital, Aalst, Belgium.
Van der Spek
P
P
Vanderlinden
I
I
Bollen
J
J
Laukens
P
P
D000328:Adult; D020117:Cisapride; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D004947:Esophagus / Q000502:physiology*; D006801:Humans; D010528:Peristalsis / Q000187:drug effects; D010880:Piperidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013268:Stimulation, Chemical
D010880:Piperidines; D012702:Serotonin Antagonists; D020117:Cisapride